JP2009539984A5 - - Google Patents

Download PDF

Info

Publication number
JP2009539984A5
JP2009539984A5 JP2009515443A JP2009515443A JP2009539984A5 JP 2009539984 A5 JP2009539984 A5 JP 2009539984A5 JP 2009515443 A JP2009515443 A JP 2009515443A JP 2009515443 A JP2009515443 A JP 2009515443A JP 2009539984 A5 JP2009539984 A5 JP 2009539984A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
carboxamide
dihydro
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009515443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539984A (ja
JP5226678B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/013721 external-priority patent/WO2007146248A2/en
Publication of JP2009539984A publication Critical patent/JP2009539984A/ja
Publication of JP2009539984A5 publication Critical patent/JP2009539984A5/ja
Application granted granted Critical
Publication of JP5226678B2 publication Critical patent/JP5226678B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009515443A 2006-06-12 2007-06-12 安定性ラキニモド製剤 Expired - Fee Related JP5226678B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81324706P 2006-06-12 2006-06-12
US60/813,247 2006-06-12
PCT/US2007/013721 WO2007146248A2 (en) 2006-06-12 2007-06-12 Stable laquinimod preparations

Publications (3)

Publication Number Publication Date
JP2009539984A JP2009539984A (ja) 2009-11-19
JP2009539984A5 true JP2009539984A5 (cg-RX-API-DMAC7.html) 2012-03-08
JP5226678B2 JP5226678B2 (ja) 2013-07-03

Family

ID=38832466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009515443A Expired - Fee Related JP5226678B2 (ja) 2006-06-12 2007-06-12 安定性ラキニモド製剤

Country Status (27)

Country Link
US (3) US7989473B2 (cg-RX-API-DMAC7.html)
EP (1) EP2035001B1 (cg-RX-API-DMAC7.html)
JP (1) JP5226678B2 (cg-RX-API-DMAC7.html)
KR (4) KR20160013273A (cg-RX-API-DMAC7.html)
CN (1) CN101466379B (cg-RX-API-DMAC7.html)
AR (1) AR061348A1 (cg-RX-API-DMAC7.html)
AT (1) ATE532515T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007258366B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0713694A2 (cg-RX-API-DMAC7.html)
CA (2) CA2899472C (cg-RX-API-DMAC7.html)
CY (1) CY1113003T1 (cg-RX-API-DMAC7.html)
DK (1) DK2035001T3 (cg-RX-API-DMAC7.html)
EA (1) EA018031B1 (cg-RX-API-DMAC7.html)
ES (1) ES2377149T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120093T1 (cg-RX-API-DMAC7.html)
IL (1) IL195724A (cg-RX-API-DMAC7.html)
MX (1) MX2008015808A (cg-RX-API-DMAC7.html)
NO (1) NO342485B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ573846A (cg-RX-API-DMAC7.html)
PL (1) PL2035001T3 (cg-RX-API-DMAC7.html)
PT (1) PT2035001E (cg-RX-API-DMAC7.html)
RS (1) RS52169B (cg-RX-API-DMAC7.html)
SI (1) SI2035001T1 (cg-RX-API-DMAC7.html)
TW (1) TWI400073B (cg-RX-API-DMAC7.html)
UA (1) UA96449C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007146248A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200810790B (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
KR101440982B1 (ko) 2005-10-19 2014-09-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 제조방법
ATE532515T1 (de) 2006-06-12 2011-11-15 Teva Pharma Stabile laquinimod-zubereitungen
RS53199B (sr) * 2007-12-20 2014-06-30 Teva Pharmaceutical Industries Ltd. Stabilni preparati lakvinimoda
EP2337779B1 (en) * 2008-09-03 2017-04-19 Teva Pharmaceutical Industries Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
AU2010260455A1 (en) * 2009-06-19 2012-02-02 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
JP5882208B2 (ja) * 2009-07-30 2016-03-09 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドによるクローン病の治療
RS55071B1 (sr) 2009-08-10 2016-12-30 Teva Pharma Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
CN102781240A (zh) * 2010-03-03 2012-11-14 泰华制药工业有限公司 用拉喹莫德和甲氨蝶呤的组合治疗类风湿性关节炎
MX342001B (es) * 2010-03-03 2016-09-09 Teva Pharmaceutical Ind Ltd * Tratamiento de artritis por lupus usando laquinimod.
BR112012021905A2 (pt) 2010-03-03 2015-09-29 Teva Pharma tratamento de nefrite lúpica usando laquinimod
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
CN102985090B (zh) * 2010-07-09 2014-11-26 泰华制药工业有限公司 5-氯-4-羟基-1-甲基-2-氧代-n-苯基-1,2-二氢喹啉-3-甲酰胺、其盐和用途
SG10201509831XA (en) * 2010-12-07 2015-12-30 Teva Pharma Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
EP2736336A4 (en) * 2011-07-28 2015-03-04 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND INTERFERON-BETA
KR20140054166A (ko) * 2011-07-28 2014-05-08 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 및 글라티라머 아세테이트의 병용에 의한 다발성 경화증의 치료
WO2013055907A1 (en) * 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
MX2014009373A (es) 2012-02-03 2014-08-27 Teva Pharma Uso de laquinimod para tratar pacientes con enfermedad de crohn que fallaron en la terapia de anti-tnfa de primera linea.
CN104114172A (zh) 2012-02-16 2014-10-22 泰华制药工业有限公司 N-乙基-n-苯基-1,2-二氢-4,5-二-羟基-1-甲基-2-氧代-3-喹啉甲酰胺、其制备和用途
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201350467A (zh) * 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
WO2014004733A1 (en) * 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410243A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
TW201410244A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EP2916915A4 (en) * 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
CN105163737A (zh) * 2013-02-15 2015-12-16 梯瓦制药工业有限公司 用拉喹莫德治疗多发性硬化症
EP2970129A2 (en) * 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
US20160038435A1 (en) 2013-03-14 2016-02-11 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
AU2014342917A1 (en) * 2013-09-27 2016-04-21 Teva Pharmaceutical Industries Ltd. Laquinimod combination therapy for treatment of multiple sclerosis
CA2933380A1 (en) * 2013-12-20 2015-06-25 Esther Lukasiewicz Hagai Use of laquinimod to delay huntington's disease progression
HK1225969A1 (zh) * 2014-01-17 2017-09-22 Teva Pharmaceutical Industries Ltd 利用低剂量的拉喹莫德治疗克隆氏病
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN110193014B (zh) * 2019-06-06 2021-05-11 温州医科大学 一种注射用拉喹莫德胶束冻干制剂及制备方法、拉喹莫德注射制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3024257A (en) * 1961-04-10 1962-03-06 Frosst & Co Charles E Stable preparations of alkali metal salts of estrone sulfate
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
CH687615A5 (de) * 1994-09-07 1997-01-15 R W Johnson Pharmaceutical Res Tropen-Verpackung.
US5912349A (en) 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
PL352882A1 (en) 1999-06-07 2003-09-22 Altana Pharma Ag Novel preparation and administration form comprising an acid-labile active compound
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
RS51019B (sr) 1999-10-25 2010-10-31 Active Biotech Ab. Lekovi za lečenje malignih tumora
JP2002031610A (ja) 2000-07-14 2002-01-31 Ajinomoto Co Inc 生体分子複合体の界面残基を同定する方法
US6307050B1 (en) 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6802422B2 (en) * 2000-12-12 2004-10-12 Multi-Comp, Inc. Sealed blister assembly
US6706733B2 (en) 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US20030119826A1 (en) 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
AU2003300692A1 (en) 2003-10-30 2005-05-19 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
KR101440982B1 (ko) 2005-10-19 2014-09-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 제조방법
ATE532515T1 (de) 2006-06-12 2011-11-15 Teva Pharma Stabile laquinimod-zubereitungen
US20080087929A1 (en) * 2006-10-11 2008-04-17 Infineon Technologies Ag Static random access memory with thin oxide capacitor
RS53199B (sr) 2007-12-20 2014-06-30 Teva Pharmaceutical Industries Ltd. Stabilni preparati lakvinimoda
EP2337779B1 (en) 2008-09-03 2017-04-19 Teva Pharmaceutical Industries Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
AU2010260455A1 (en) 2009-06-19 2012-02-02 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
JP5882208B2 (ja) 2009-07-30 2016-03-09 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドによるクローン病の治療
RS55071B1 (sr) 2009-08-10 2016-12-30 Teva Pharma Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
CN102781240A (zh) 2010-03-03 2012-11-14 泰华制药工业有限公司 用拉喹莫德和甲氨蝶呤的组合治疗类风湿性关节炎
MX342001B (es) 2010-03-03 2016-09-09 Teva Pharmaceutical Ind Ltd * Tratamiento de artritis por lupus usando laquinimod.
BR112012021905A2 (pt) 2010-03-03 2015-09-29 Teva Pharma tratamento de nefrite lúpica usando laquinimod
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
CN102985090B (zh) 2010-07-09 2014-11-26 泰华制药工业有限公司 5-氯-4-羟基-1-甲基-2-氧代-n-苯基-1,2-二氢喹啉-3-甲酰胺、其盐和用途

Similar Documents

Publication Publication Date Title
JP2009539984A5 (cg-RX-API-DMAC7.html)
JP6228544B2 (ja) ニコチン含有治療用組成物のための賦形剤
JP5226678B2 (ja) 安定性ラキニモド製剤
EP3284467B1 (en) Nicotine-containing pharmaceutical compositions
ME02477B (me) Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapiji
JP2015515459A5 (cg-RX-API-DMAC7.html)
JP2013535505A5 (cg-RX-API-DMAC7.html)
WO2008144730A3 (en) Stable pharmaceutical formulation for a dpp-iv inhibitor
CN102933199A (zh) 含有烟碱的药物组合物
WO2012048846A3 (de) Phosphatbinderformulierung zur einfachen einnahme
JP2015533134A5 (cg-RX-API-DMAC7.html)
IL292465B1 (en) Neuroactive compounds and methods of using them
WO2009112274A3 (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP2014503593A5 (cg-RX-API-DMAC7.html)
JP2015527321A5 (cg-RX-API-DMAC7.html)
WO2008116601A3 (en) Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
JP2018521007A5 (cg-RX-API-DMAC7.html)
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
NZ611026A (en) Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria
JP2008534522A5 (cg-RX-API-DMAC7.html)
WO2008111674A1 (ja) 口腔粘膜貼付ブプレノルフィン製剤の製造方法
EA201170784A1 (ru) Гранулы тамсулозина для фиксированной комбинации
CA2565993A1 (en) Salt of 4-or 5- aminosalicylic acid
TW200833708A (en) Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture
JP2019514977A5 (cg-RX-API-DMAC7.html)